TR199600438A2 - Piperazin türevleri. - Google Patents

Piperazin türevleri.

Info

Publication number
TR199600438A2
TR199600438A2 TR96/00438A TR9600438A TR199600438A2 TR 199600438 A2 TR199600438 A2 TR 199600438A2 TR 96/00438 A TR96/00438 A TR 96/00438A TR 9600438 A TR9600438 A TR 9600438A TR 199600438 A2 TR199600438 A2 TR 199600438A2
Authority
TR
Turkey
Prior art keywords
piperazine derivatives
piperazine
derivatives
Prior art date
Application number
TR96/00438A
Other languages
English (en)
Turkish (tr)
Inventor
Masaaki Matsuo
Daijiro Hagiwara
Takashi Manabe
Nabukiyo Konishi
Shinji Shigenaga
Kenji Murano
Hiroshi Matsuda
Hiroshi Miyake
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of TR199600438A2 publication Critical patent/TR199600438A2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
TR96/00438A 1995-05-25 1996-05-24 Piperazin türevleri. TR199600438A2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45017695A 1995-05-25 1995-05-25

Publications (1)

Publication Number Publication Date
TR199600438A2 true TR199600438A2 (tr) 1996-12-21

Family

ID=23787083

Family Applications (1)

Application Number Title Priority Date Filing Date
TR96/00438A TR199600438A2 (tr) 1995-05-25 1996-05-24 Piperazin türevleri.

Country Status (14)

Country Link
EP (1) EP0846116A1 (fr)
JP (1) JP3071829B2 (fr)
KR (1) KR19990021857A (fr)
CN (1) CN1072220C (fr)
AU (1) AU706021B2 (fr)
CA (1) CA2222041A1 (fr)
EA (1) EA000669B1 (fr)
HU (1) HUP9900822A3 (fr)
IL (1) IL118369A (fr)
NZ (1) NZ307625A (fr)
TR (1) TR199600438A2 (fr)
TW (1) TW391960B (fr)
WO (1) WO1996037489A1 (fr)
ZA (1) ZA964101B (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2189501A1 (fr) * 1995-11-06 1997-05-07 Harry R. Howard Antagonistes des recepteurs de nk-1 pour le traitement du cancer
ATE219064T1 (de) * 1995-12-18 2002-06-15 Fujisawa Pharmaceutical Co Piperazinderivative als tachykinin antagonisten
AUPO735997A0 (en) * 1997-06-17 1997-07-10 Fujisawa Pharmaceutical Co., Ltd. Piperazine derivatives
DE59814233D1 (de) * 1997-08-27 2008-07-03 Solvay Pharm Gmbh Indolmethyl-N,N'-bisacylpiperazine als Neurokininrezeptorantagonisten
DE19824865A1 (de) * 1997-08-27 1999-03-04 Solvay Pharm Gmbh Neue Harnstoffderivate
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
DE10036818A1 (de) * 2000-07-28 2002-02-07 Solvay Pharm Gmbh Neue N-Triazolylmethyl-Piperazinderivate als Neurokininrezeptor-Antagonisten
UA75425C2 (en) * 2001-07-09 2006-04-17 Piperazine oxime derivatives with antagonistic activity to nk-1 receptor, use thereof, a pharmaceutical composition based thereon, a method for producing and a method for producing intermediary compounds
UA77515C2 (en) 2002-04-04 2006-12-15 Diazabicyclo alkane derivatives possessing neuroldnin-nk1 receptor antagonistic activity
MX2007000428A (es) 2004-07-15 2008-03-05 Amr Technology Inc Tetrahidroisoquinolinas sustituidas con arilo y heteroarilo y uso de las mismas para bloquear la captacion de norepinefrina, dopamina y serotonina.
ATE550019T1 (de) 2005-05-17 2012-04-15 Merck Sharp & Dohme Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
CA2615403C (fr) 2005-07-15 2015-06-16 Amr Technology, Inc. Tetrahydrobenzazepines substituees par aryle et heteroaryle, et leur utilisation pour bloquer la reabsorption de la noradrenaline, de la dopamine, et de la serotonine
AU2006297443B2 (en) 2005-09-29 2010-08-12 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
CA2664113C (fr) 2006-09-22 2013-05-28 Merck & Co., Inc. Utilisation de la platencine et de la platensimycine en tant qu'inhibiteurs de la synthese des acides gras pour traiter l'obesite, lediabete et le cancer
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
EP2109608B1 (fr) 2007-01-10 2011-03-23 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Indazoles à substitution amide utilisés comme inhibiteurs de la poly(adp-ribose)polymérase (parp)
CN101641099A (zh) 2007-01-24 2010-02-03 葛兰素集团有限公司 包含3,5-二氨基-6-(2,3-二氯苯基)-1,2,4-三嗪或r(-)-2,4-二氨基-5-(2,3-二氯苯基)-6-氟甲基嘧啶和nk1的药物组合物
US8106086B2 (en) 2007-04-02 2012-01-31 Msd K.K. Indoledione derivative
WO2008147864A2 (fr) * 2007-05-22 2008-12-04 Xenon Pharmaceuticals Inc. Procédés d'utilisaton de composés pipérazine dans le traitement de maladies ou états médiés par le canal sodium
JP5501227B2 (ja) 2007-06-27 2014-05-21 メルク・シャープ・アンド・ドーム・コーポレーション ヒストンデアセチラーゼ阻害剤としての４−カルボキシベンジルアミノ誘導体
AU2009222122A1 (en) 2008-03-03 2009-09-11 Tiger Pharmatech Tyrosine kinase inhibitors
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
EP2413932A4 (fr) 2009-04-01 2012-09-19 Merck Sharp & Dohme Inhibiteurs de l'activité akt
KR20120034644A (ko) 2009-05-12 2012-04-12 알바니 몰레큘라 리써치, 인크. 아릴, 헤테로아릴, 및 헤테로사이클 치환된 테트라하이드로이소퀴놀린 및 이의 용도
EP2429293B1 (fr) 2009-05-12 2014-10-29 Bristol-Myers Squibb Company FORMES CRISTALLINES DE (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN -6-YL)-4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE ET LEURS UTILISATIONS
ES2662072T3 (es) 2009-05-12 2018-04-05 Albany Molecular Research, Inc. 7-([1,2,4]triazolo[1,5-a]piridin-6-il)-4-(3,4-diclorofenil)-1,2,3,4-tetrahidroisoquinolina y uso de la misma
KR101485645B1 (ko) 2009-10-14 2015-01-22 머크 샤프 앤드 돔 코포레이션 ｐ53 활성을 증가시키는 치환된 피페리딘 및 그의 용도
WO2011163330A1 (fr) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Nouveaux composés hétérocycliques utilisés comme inhibiteurs de erk
CN107090456B (zh) 2010-08-02 2022-01-18 瑟纳治疗公司 使用短干扰核酸的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1基因表达的抑制
HUE044815T2 (hu) 2010-08-17 2019-11-28 Sirna Therapeutics Inc Hepatitisz B vírus (HBV) génexpressziójának RNS-interferencia közvetített gátlása, rövid interferáló nukleinsav (SINS) alkalmazásával
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
WO2012030685A2 (fr) 2010-09-01 2012-03-08 Schering Corporation Dérivés d'indazole utilisables en tant qu'inhibiteurs de la voie erk
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
WO2012058210A1 (fr) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. INHIBITION FACILITÉE PAR L'INTERFÉRENCE D'ARN DE L'EXPRESSION D'UN GÈNE AU MOYEN D'ACIDES NUCLÉIQUES INTERFÉRENTS COURTS (siNA)
US9351965B2 (en) 2010-12-21 2016-05-31 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
CN103732592A (zh) 2011-04-21 2014-04-16 默沙东公司 胰岛素样生长因子-1受体抑制剂
US9023865B2 (en) 2011-10-27 2015-05-05 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
EP3919620A1 (fr) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Compositions d'acide nucléique interférent court (sina)
CA2882950A1 (fr) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Nouveaux composes inhibiteurs de erk
LT2925888T (lt) 2012-11-28 2018-01-10 Merck Sharp & Dohme Corp. Vėžio gydymo kompozicijos ir būdai
BR112015013611A2 (pt) 2012-12-20 2017-11-14 Merck Sharp & Dohme composto, e, composição farmacêutica
WO2014120748A1 (fr) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. Purines 2,6,7,8-substituées utilisées en tant qu'inhibiteurs de hdm2
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
US20210309688A1 (en) 2018-08-07 2021-10-07 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US20210277009A1 (en) 2018-08-07 2021-09-09 Merck Sharp & Dohme Corp. Prmt5 inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2097142T3 (es) * 1989-02-10 1997-04-01 Otsuka Pharma Co Ltd Derivados de indol, su preparacion y medicamento que los contiene destinado para la prevencion y para el tratamiento de la nefritis.
IL111730A (en) * 1993-11-29 1998-12-06 Fujisawa Pharmaceutical Co Piperazine derivatives, processes for their preparation and pharmaceutical preparations containing them

Also Published As

Publication number Publication date
EP0846116A1 (fr) 1998-06-10
NZ307625A (en) 1999-02-25
IL118369A (en) 2000-06-01
CN1072220C (zh) 2001-10-03
WO1996037489A1 (fr) 1996-11-28
TW391960B (en) 2000-06-01
IL118369A0 (en) 1996-09-12
AU5703196A (en) 1996-12-11
CA2222041A1 (fr) 1996-11-28
AU706021B2 (en) 1999-06-03
JP3071829B2 (ja) 2000-07-31
ZA964101B (en) 1996-07-29
EA199700425A1 (ru) 1998-12-24
JPH11505830A (ja) 1999-05-25
KR19990021857A (ko) 1999-03-25
HUP9900822A3 (en) 1999-11-29
CN1191533A (zh) 1998-08-26
EA000669B1 (ru) 2000-02-28
HUP9900822A2 (hu) 1999-06-28

Similar Documents

Publication Publication Date Title
TR199600438A2 (tr) Piperazin türevleri.
BR9712037A (pt) Derivados de piperazina
DE59813899D1 (de) Piperazin-derivate
NL300214I2 (nl) Chinazolinederivaten.
DK0831829T3 (da) Heterocykliske, ringkondenserede pyrimidinderivater
TR199501463A2 (tr) Triazolil türevleri.
DE59501802D1 (de) Substituierte 1H-3-Aryl-pyrrolidin-2,4-dion-Derivate
MX9205145A (es) Nuevos derivados heterociclicos.
PT901474E (pt) Derivados de aril-pirimidina.
IS4963A (is) Setnar 6,5-heteró-bísýklískar afleiður
TR199501634A2 (tr) Piperazin türevleri,bunlari ihtiva eden ilaclar,bunlarin kullanilmasi ve imal edilmesine mahsus usul.
TR199600883A2 (tr) Pürin-6-on türevleri.
DE69930543D1 (de) Piperazin-derivate
DE69511086T2 (de) Pyrimidinderivate
NO972937D0 (no) Farmasöytiske piperazinforbindelser
DK0922050T3 (da) 3-Descladinose-2,3-anhydroerythromycin-derivater
ZA966048B (en) Piperazine derivatives.
ATE266637T1 (de) 3,3-biarylpiperidin- und 3,3- biarylmorpholinderivate
TR199800988A3 (tr) 5' Deoksi-Sitidin türevleri.
TR27090A (tr) Tetrahidropirimidin türevleri.
ATE227282T1 (de) 2,4-diaminopyrimidin-derivate
TR199600715A2 (tr) Kefalosforin türevleri.
TR199600701A2 (tr) 9-ikameli 2-(2-n-alkoksifenil)-pürin-6-onlar.
DE69524611T2 (de) Pyrimidon-derivate
TR28915A (tr) Naftokinon türevleri.